T Cell Lineage Commitment: Identity and Renunciation by Rothenberg, Ellen V.
T cell lineage commitment: identity and renunciation1
Ellen V. Rothenberg
Division of Biology 156-29, California Institute of Technology, Pasadena, CA 91125
Abstract
Precursors undertaking T-cell development shed their access to other pathways in a sequential
process that begins before entry into the thymus and continues through many cell cycles
afterwards. This process involves three levels of regulatory change, in which the cells’ intrinsic
transcriptional regulatory factors, expression of signaling receptors like Notch1, and expression of
distinct homing receptors separately contribute to confirmation of T-cell identity. Each alternative
potential has a different underlying molecular basis which is neutralized, then permanently
silenced through different mechanisms in early T-cell precursors. This regulatory mosaic has
notable implications for the hierarchy of relationships linking T lymphocytes to other
hematopoietic fates.
Commitment versus potential
Multipotent hematopoietic cells gain access to the T-cell developmental pathway, and then
confirm that choice of fate by “burning their bridges” to other pathways. The process
involves a continuing dialogue between the differentiating cell and the signals coming from
its environment. Best understood of these signals are effects of Notch1 engagement with
Delta ligands provided in the environment of the thymus, which are needed for T-cell
specification throughout the lineage choice process, and only become dispensable after T-
cell fate is confirmed (1-3). In vivo, expression of Notch ligand with supportive cytokines
such as IL-7 and Kit ligand gives the thymus its T-cell inductive activity (3). However, the
cells that begin the T cell program initially have access to other options. These can be
revealed if the cells are removed from the thymic environment and challenged with different
environmental signals. Only after they lose the ability to make these alternative responses
are the cells committed.
Commitment is the cell-intrinsic regulatory transformation through which a cell's alternative
potentials are eliminated. “Potential” is not the same as the default fate that a cell adopts in
an undisturbed condition. “Fate” is the intersection between the cell's potential and the
permissive or nonpermissive circumstances in which a cell finds itself. For a typical
uncommitted cell, the fates its progeny actually adopt in vivo may be only a slice of the
uncommitted cell's full potential, because environmental conditions are limiting. As the cell
progresses toward commitment, its potential shrinks. At the point where potential rather than
environment becomes limiting for fate, the cell is committed. Interestingly, one of the few
cases where a “fate” assay approaches a “potential” assay is in the case of hematopoietic
stem cells, where extremely long assay times are conventionally used, extremely large
numbers of progeny are generated before the endpoint, and the intermediates include highly
motile cells that can sample an unusually large number of in vivo environments before
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differentiating as scored at the assay endpoint. However, this exception proves the rule that
multipotent cells can only show the subset of their potentials that their environments
support.
If fate is different from potential, then why study potential at all (4,5)? Potential reveals
what the regulatory machinery of the cell itself, transcription factors and signal receptors,
contributes to its identity. The commitment process establishes an irreversible, portable,
unconditional identity by actively narrowing a cell's range of potentials. Exclusion of any
particular fate can occur by repression either of a key transcription factor or of a signaling
receptor that would be needed to induce that pathway in permissive conditions. For example,
T cell potential itself depends on Notch1 expression. During B-lineage commitment, T-cell
potential is excluded by Pax5's silencing the expression of Notch1 (6). Ultimately,
commitment to a lineage is the readout for the gene regulatory network that links positive
differentiation in one pathway with the controlled silencing of particular transcription factors
and signaling receptors needed for other pathways.
Normally developmental potentials of two populations are compared by testing cells under
uniform conditions that are clearly permissive for the fates being assayed. However, there
are caveats. When hematopoietic precursors are adoptively transferred intravenously, the
protocol in effect “hands over” to the grafted cells themselves the ultimate choice of the
environment into which they will lodge. The choice is mediated by adhesion molecules and
chemokine receptors on the cells that can bias migration to particular microenvironments,
and these “traffic control” molecules are themselves developmentally regulated. For
example, the chemokine receptors CCR9 and/or CCR7 are needed for hematopoietic
precursors to enter the thymus; double mutants are dramatically impaired as T-cell
precursors in vivo (7-9). The abilities of cells to home predictably to particular environments
in vivo are biologically important and especially relevant for therapeutic use of uncommitted
cells in clinical practice (5). However, these traffic control molecules are not needed under
permissive conditions to program T-cell identity itself (10).
Thus, changes in cell potential need to be explained by mechanisms operating at three
distinct levels. At the cell-intrinsic level, potential is defined by transcription factors and
possible epigenetic constraints. At the opposite extreme, in cases where the environment is
not experimentally controlled, the cell's opportunities may be biased by its migration
preferences. Between these levels, at the cell/environment interface, triggering of potential
depends on expression of signaling receptors that modify transcription factor activity in
response to inductive environmental signals.
Stepwise commitment of T-cell precursors
Hematopoietic stem cells begin with access to 10 or more distinguishable fates, including
erythroid and megakaryocytic, macrophage, neutrophilic granulocyte, eosinophil, basophil,
mast cell, conventional dendritic cell, plasmacytoid dendritic cell, natural killer (NK) cell, T
lymphocyte, and B lymphocyte as well as their subtypes. In the T cell pathway, there is an
ordered loss of access to these fates. Thus, commitment emerges as the end of a sequential
process of lineage exclusions, summarized in Fig. 1. Before arrival in the thymus, precursors
have already lost the ability to make erythroid cells and megakaryocytes, but the most
immature cells in the thymus clearly retain access to dendritic cell, natural killer cell,
macrophage and granulocyte, and probably also mast-cell and B cell potential in addition to
T-cell potential. The B cell potential is rapidly extinguished (11). In fetal mouse T-cell
development, B potential is lost even before the cells arrive in the thymus (12,13). However,
NK, DC, and even macrophage and granulocyte (“myeloid”) potential remain evident until a
later intrathymic stage, in both fetal and postnatal cases, if the cells are tested under
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permissive conditions. These NK and DC potentials then disappear at a distinct, later
transition between “DN2” (c-Kit+ CD44+ CD25+) and “DN3” (c-Kitlow CD44- CD25+)
(14-18), more finely mapping between the “DN2a” (c-Kit++) and “DN2b”(c-Kit+) stages
(19,20). Single cells in the DN2 (DN2a) stage can still give rise to clones including T cells
as well as NK cells, macrophages, or dendritic cells, or even granulocytes (15,16,18,21,22);
in contrast, cells one stage later (DN2b stage) can no longer do this (19,20). This last step of
alternative fate exclusion completes T lineage commitment.
T-lineage gene expression is fully activated by the DN3 stage (20). The genes required for
T-cell receptor (TCR) expression and function are turned on asynchronously, depending on
gene-specific combinations of inputs from the transcription factors that are needed for early
T-cell development, including GATA-3, TCF-1, basic helix-loop-helix (bHLH) E proteins
E2A and HEB (Tcf12), Runx/CBFβ complexes, and the Notch-activated transcription factor
RBPJκ (CSL) (23). In detail, the induction of T-cell genes still remains poorly explained.
None of the essential factors seems dominant in the way that GATA-1 is for erythroid genes
(24). However, these factors also participate individually in aspects of lineage exclusion, as
described below.
Notch signaling in B and myeloid lineage exclusion
As long as immature thymocytes remain undisturbed in the thymus, their prevalent fate will
normally be to generate T-cell progeny, with few NK, dendritic or myeloid progeny, and no
B-cell progeny (25,26). Notch signaling makes this in vivo environment non-permissive for
display of B, myeloid, and NK alternative potentials. Notch can block these alternative
pathways even if the cells are forced to express ectopic transcription factors of other
lineages that would otherwise impose lineage conversion (18,27-29). Thus, it is only when
cells are removed from Notch signaling that distinct levels of restriction are seen. B lineage
repression becomes independent of Notch signaling within a few cell divisions after thymic
entry (11), when the cells are still in the initial “early T-cell precursor” (ETP/DN1, c-Kit++
CD44+ CD25-) compartment (Fig. 1), although Notch is still needed at that stage to keep
myeloid potential at bay. Myeloid and dendritic lineage exclusions only become Notch
independent later, at the DN2b stage (19,20) during commitment.
“Regulatory bridges” to myeloid and dendritic potential
Hematopoietic precursors, both in the bone marrow and in the early intrathymic stages,
simultaneously express some levels of transcription factors that participate in disparate fates,
as well as many of the target genes associated with these contradictory pathways (30,31).
Indeed, early T cell precursors share certain transcription factors with the ensembles that
guide differentiation of B and myeloid cells. T cells share with B cells the use of E proteins,
Myb, Runx1/CBFβ, and Ikaros, and both initially share with myeloid cells the use of the
ETS-family factor PU.1. In the myeloid case, potential appears to be controlled through
effects on the shared factors that make a “bridge” from the T-cell pathway.
Myeloid potential reflects activity of the bZIP transcription factor C/EBPα together with the
Ets-family factor PU.1 (32), which is also essential for generation of lymphoid-primed
multipotent precursors (33,34). These play roles in virtually all myeloid cells, can upregulate
each other (35), and together can convert even fibroblasts directly into macrophages (36).
Myeloid growth factor receptor signaling from the environment can promote myeloid
differentiation in part by post-translationally enhancing PU.1 activity (37-39). Since the
myeloid growth factor receptors themselves are among the major target genes of PU.1
activation (40,41), PU.1 enables environmental myelopoietic growth factors to activate a
positive feedback circuit to drive myeloid development. Both “myeloid” factors are present,
or inducible, at stages when myeloid potential of thymocytes is highest. Prethymic
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precursors as well as ETP and DN2a pro-T cells all express moderately high levels of PU.1
(20,34). As the cells undergo commitment PU.1 is downregulated, with expression
decreased by about a hundredfold by the time cells reach the DN3-stage checkpoint (20).
Although C/EBPα expression is low in ETPs and silenced soon afterwards, lineage-tracing
experiments also confirm that many T cells are indeed generated from C/EBPα+ precursors
as well (42). Adding back either PU.1 or C/EBPα to committed, DN3 stage thymocytes
restores myeloid potential; in the absence of Notch signals either factor can promote the
reactivation of the other (27,28,43,44). These factors thus provide a clear way to understand
why the ETP and DN2a thymocytes can still differentiate into myeloid cells, whereas DN2b
and later stage cells normally cannot.
PU.1 is also crucial for development of almost all types of dendritic cells, in part due to its
regulation of the growth factor receptor Flt3 (41). Although conventional and plasmacytoid
dendritic cells develop from different programs that diverge sharply in their use of E
proteins, both depend on PU.1 for generation (41) and require expression thereafter of PU.1-
subfamily ETS factors, PU.1 or SpiB respectively (45). The ability of PU.1 and SpiB to
support DC development can even be detected in the presence of some continuing Notch
signaling (43) (M. M. Del Real and E. V. R., unpublished results), when C/EBP factors are
not activated. Thus, it is not surprising that dendritic cell potential in thymocytes also
closely tracks the natural expression of PU.1.
Lymphoid vs. myeloid lineage choice machinery
C/EBPα expression in thymocytes is limited by Notch signaling (46), possibly through the
Notch-induced repressor Hes1 (47). It probably begins to be inhibited soon after thymic
entry, since Notch targets including Hes1 are active in pro-T cells throughout the ETP to
DN3a stages. Recent data from our own lab's genome-wide epigenetic mapping studies
confirm that repression machinery has already begun to be recruited to the Cebpa gene,
based on H3K27me3 histone marks, as early as the ETP/DN1 stage (J. Zhang, A. Mortazavi,
B. Williams, B. J. Wold, E.V.R., unpublished); however, as noted above, it can still be
reactivated at a later stage if PU.1 levels are high and Notch signals are removed. Under
normal conditions, its expression limit may be set by the increasing dependence of pro-T
cells on Notch signals for viability as they pass the DN2a to DN2b transition, discussed
below (20).
The mechanism that represses PU.1 between the DN2a and DN3 stages is different. Two
cis-regulatory regions of the Sfpi1 (PU.1) gene appear to mediate repression: a
multifunctional Upstream Regulatory Element (48,49), and a recently described, cell-type
specific silencer (50). Runx1/CBFβ complexes appear to repress at both elements. Two
other factors may also contribute to PU.1 repression, namely TCF-1 (encoded by the Tcf7
gene) and Gfi1, both of which can work through sites near the Upstream Regulatory
Element (51,52). Finally, GATA-3 appears to antagonize PU.1 expression with a very
sensitive dose-response, although the mechanism may not be direct (29)[D. D. Scripture-
Adams, A. M. Arias, K. J. Elihu, M. Zarnegar, and E. V. R., unpublished results]. The
details of mechanism explaining the timing, magnitude, and near-permanence of the
repression need further study, but it is notable that GATA-3, Runx1/CBFβ, and TCF-1 all
play direct roles in the positive regulation of T-cell genes as well.
It is revealing to compare these lineage choice mechanisms in early T cells with the gene
regulatory networks that have been proposed to explain other cell fate choices, where each
cell type requires PU.1 but at different levels (52,53). In myeloid vs. B lineage fate choice,
access to the B-cell fate appears to depend on PU.1 restrained by Ikaros plus E2A (52). The
switch function at the heart of this network comprises “myeloid” Id2 and Egr2 on one side,
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induced by high-level PU.1, with Gfi1 on the other, which is turned on by E2A and Ikaros
and itself helps to limit PU.1 expression. Superficially, the early pro-T cell regulatory
environment seems like that of the early B cell, with strong expression of Ikaros and Gfi1
and steady activity of E proteins, and with little C/EBPα, Egr2, or Id2. However, although
both early B and early T cells need to restrain PU.1 using shared lymphoid factors, in one
respect their two networks give quite different results as PU.1's activity is antagonized. In
early T cells, the B cell option has already been closed off irreversibly, even before Runx1,
TCF-1, and Gfi1 help to silence PU.1.
Candidate mechanisms in B lineage exclusion
How can the B cell fate be excluded so early? The B cell fate should be connected to the T
cell program by an overabundance of “regulatory bridges”. B cells share with T cells the use
of RAG-dependent gene rearrangement to assemble the immunoglobulin superfamily
immune receptors, a common sequence of immune receptor-dependent developmental
checkpoints, and and extensive analogies in morphology and signal processing, as well as
sustained requirements for transcription factors including E2A and Ikaros, and IL-7Rα/γc
signaling. Furthermore, whereas the thymic stroma does not produce myeloid growth factors
normally, it provides a rich source of the IL-7 that B cell precursors need to grow (3). This
makes it easy to understand why the thymus fills with B cells when Notch signaling is
impaired (26,54). However, even after just a few days of contact with Notch signals,
thymus-settling precursors lose the ability to make B cells even when switched to B-cell
conditions, while their ability to make myeloid cells, under optimal in vitro conditions,
remains intact.
The B lineage exclusion mechanism must inactivate some crucial B-cell function that T and
B cells do not share. The B-cell specifically expressed factors EBF1 and Pax5, both essential
for B cell development in a mutual positive feedback loop (55), are likely to be the crucial
control points. Neither of these factors is detectably expressed in any early thymocyte or in
vitro differentiated pro-T cell population from the ETP stage onward (56-58). Heavy histone
H3K27me3 marks, deposited across these loci as early as the ETP stage, also imply that
these genes are silenced epigenetically (J. Zhang, A. Mortazavi, B. Williams, B. J. Wold, &
E.V.R., unpublished). This correlates well with the cells’ inability to switch to the B-cell fate
from the later ETP stage onward.
Nevertheless, it is not yet fully clear how Notch signaling terminates access to the B-cell
fate. While there appears to be a mechanism through which Notch signaling temporarily
interferes with EBF1 function in EBF1-expressing cells (59), the permanent transcriptional
silencing of the Ebf1 and Pax5 loci needs another explanation. This is not an immediate
Notch response like Hes1 induction, as several days of Notch signaling are required for full
loss of B-cell potential (11,60). It is more coordinated with upregulation of GATA-3 and
TCF-1, the first T-cell specific transcription factors to be induced (60). Even low-dose
GATA-3 appears to be highly antagonistic to the B-cell fate (29,61-63)(D. D. Scripture-
Adams, A. M. Arias, & E.V.R., unpublished). However, GATA-3 may not antagonize the B-
lineage program alone, as Notch signaling can also block B-cell development in vitro from
GATA-3 deficient cells (64). This GATA-3-independent effect of Notch could indicate the
presence of another T-lineage specific B-cell exclusion system.
Blocking the path to the NK fate: “work never done”
The loss of NK potential, as measured by the ability to generate NK1.1.+, DX-5+, Perforin+
cells lacking T cell markers when supportive cytokines are provided, occurs after the DN2a
stage, similarly timed but probably slightly later than the loss of myeloid and dendritic
potential (18-20). NK cell fate is now understood as a complex cluster of programs (65), but
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in general they all have a great deal in common with T-cell subset programs. Most of the
transcription factors NK cells use are shared with T cells, and there is a thymically derived
lineage of NK cells that makes use of GATA-3 and IL-7R very much like T cells (66).
Although genes expressed by NK cells are often used as markers for NK cell fate choice,
most are also expressed by invariant NK T cells and some TCRγδ cells after their TCR-
dependent selection. Thus, the problem with defining how T-cell precursors lose NK
potential is that it is uncertain whether access to the “NK” program is ever fully lost at all, or
simply restrained until a later stage when it can be redeployed for cytolytic T cell functions.
For years, the only candidate “master regulator” for NK cells was the helix-loop-helix
antagonist Id2. This was a frustrating candidate. Not only is it also used in later T-cell
development, but also it is not a DNA-binding factor itself at all, rather just a decoy that
blocks the ability of bHLH transcription factors (E2A, HEB) to bind to the DNA. Thus, Id2
itself has no direct regulatory targets that could explain the network of NK differentiation.
However, a great advance has been the discovery of a true sequence-specific DNA-binding
factor, Nfil3 (E4bp4), that has a crucial role in the programming of NK cells, including
induction of Id2 itself (67,68)(reviewed by (61)). Furthermore, at least one transcription
factor has been described recently, Zfp105, which may be the most specific NK cell
regulator yet (69). These factors are not part of the normal adult T-cell precursor regulatory
repertoire, and so their regulation can be considered a key to NK potential (61).
Surprisingly, it is the NK pathway for which a T-lineage-specific, dedicated negative
regulator has emerged first. This is the highly T-lineage-specific transcription factor, Bcl11b
(70-72). Bcl11b expression is induced immediately before the loss of access to the NK
option. Acute deletion of Bcl11b not only channels early T-cell precursors into an NK fate
under T-cell conditions, but also allows fully committed T-cell precursors to back
differentiate to NK cells or NK-like effectors if deletion is postponed to a later stage (72). If
cells delete Bcl11b just during β-selection, there is a severe decrease in their lifespans as
CD4+ CD8+ thymocytes, associated with aberrant activation of a number of mature cytolytic
effector genes (73) as well as other precociously activated maturation regulators suggesting
an NKT-like fate (74). Bcl11b loss allows the innate-immune cell transcription factors Nfil3
and Zbtb16 (PLZF) to be upregulated, as well as the highly NK-specific regulatory gene
Zfp105 (71,72). Bcl11b also may repress Id2 via direct binding (74). Within the T lineage,
Bcl11b is expressed continuously from the DN2b stage onward. Interestingly, its levels of
expression vary, and are in fact lowest in activated effector CD8 cells and NKT cells. NK
cells also express some Bcl11b but at lower levels still (http://www.immgen.org) (75). Thus
Bcl11b appears to be needed as a continuing restraint on the deployment of NK-like
functions, not only during early T-lineage commitment but throughout all later T-cell
development.
Commitment irreversibility: loss of self-renewal potential
Bcl11b's effects extend more broadly than to repress NK functions. One of the phenotypes
that is most striking in Bcl11b knockout pro-T cells is that they can also continue apparent
self-renewal in a precommitment DN2a-like state, growing better than wildtype cells in the
presence of Notch signals in vitro, but retaining DN2-like properties rather than progressing
in differentiation (70,71). Like normal DN2a cells, they retain access to myeloid fates (if
myeloid growth factors are supplied), though not B lineage fates, even after weeks of
exposure to strong Notch signals (70,71). They not only preserve expression of PU.1 under
these circumstances (70,71), but also preserve expression of a cluster of stem/progenitor
associated regulatory genes that are expressed in early thymocytes and normally
downregulated during commitment (20). These genes are otherwise implicated in aspects of
precursor self-renewal (71). and appear to define an initial subprogram for pro-T cell
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expansion (23). Thus, Bcl11b normally both restrains the NK option and helps to end a
discrete, precommitment expansion program (Fig. 1, “phase 1”). Notably, the termination of
this “phase 1” program (Fig. 1) is tightly correlated with an abrupt transition to extreme
Notch-dependence for survival (76), coinciding with commitment at the DN2b stage (20).
The shift to acute Notch dependence itself can contribute to the timing of commitment, as it
effectively applies a death penalty to any cell, from DN2b through β-selection, that ventures
to sample an environment free of the developmental constraints of Notch signals.
Controversial commitment trees: the Common Lymphoid Precursor and its
rivals
The use of distinct repression mechanisms to block different alternative potentials makes the
T-lineage program quite versatile in its ability to use input cells from different prethymic
commitment states. If the suite of transcription factors activated by Notch signals can
separately exclude the B-cell fate, whether the myeloid fate has been excluded before or not,
and separately block the myeloid fate, whether the B-cell fate has been excluded or not, then
there is no need to postulate only one true pipeline of prethymic cells feeding the thymus.
This is important because there is evidence that a range of different precursors can in fact
provide input into the T-cell program (rev. (77); (78-80)), though in vivo they may reach the
thymus differently and undergo differentiation vs. self-renewal expansion with different
kinetics.
While these different prethymic precursors share NK and dendritic-cell potential, and B-cell
potential if they come from postnatal animals, they differ in their perceived ability to make
myeloid cells. Thus, CCR9+ Lymphoid-primed Multipotent Precursors (LMPP) have strong
myeloid activity as well as lymphoid activity, while Common Lymphoid Precursors (CLP)
(81) and other lymphoid-biased early lymphoid precursor subsets (82-84) appear to have
much stronger B, NK, and T lymphoid potential than granulocyte or macrophage potential,
at least in vivo. But this seems to pose a logical contradiction: if many thymus-settling cells
have already lost myeloid potential, then how can myeloid potential also persist after B-cell
potential is lost?
Heterogeneity of thymus-immigrating cells can provide one answer: the myeloid potential
may be persisting only in descendants of those immigrants that were not CLP. Another
answer, however, is that the myeloid potential in CLP is not actually lost, but rather under
constraint. In fact, CLPs are also highly efficient at generating myeloid cells, similar to
intrathymic ETP and DN2a cells, provided that they are tested similarly in optimal in vitro
conditions (5,25). The largest differences in myeloid potential between CLPs and LMPPs
are seen when the cells are assayed in vivo by adoptive transfer, in which they are allowed
to determine their own homing to distinct microenvironments. Thus a strong possibility is
that “traffic control” mechanisms specific to CLPs help to make them lymphoid-restricted in
vivo, by directing them to lymphopoietic environments that are not fully permissive for
myeloid development.
This is more plausible than it might appear, because even the bone marrow itself now
appears to contain distinct domains that are permissive or restrictive for B lymphoid vs.
myeloid differentiation (85). In vivo, a G-protein coupled receptor sensitive to pertussis
toxin appears to keep CLP within the lymphopoietic domain and keep them out of the
myeloid domain. This localization is important for their behavior as lymphoid restricted
precursors, since these cells generate myeloid progeny instead, if pertussis toxin is used in
vivo to block their attraction to B lymphopoietic domains (85). The myeloid growth factor
receptor-triggered positive feedback with PU.1 provides a strong candidate mechanism that
may be needed for an environment to be myeloid-permissive. On the other hand, bone
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marrow lymphopoietic zones that promote B and NK development are likely to protect the
cells from these myeloid growth factor receptor-like signals and Toll-like receptor signals,
either of which can readily induce myeloid differentiation from CLP (86-88). Thus the
nature of the mechanisms that provide the first restraint on myeloid differentiation of
prethymic lymphoid precursors in vivo may be powerful in vivo, but qualitatively different
from the cell-intrinsic, transcriptional regulatory circuits that later extinguish myeloid
potential by silencing first EBF1 and Pax5, and then PU.1 and C/EBPα expression during T-
lineage commitment.
Conclusions
Lineage commitment in the T cell system might have been a single event driven by a single
factor, like erythroid commitment driven by GATA-1, which combines positive and
negative regulatory activities in a single potent factor (24). But there has been no evidence
to support this. Instead, the successive losses of different options for T-cell development
depend on the operation of molecularly distinct exclusion mechanisms. The environmental
effects of Notch signaling are applied only during the commitment process, to activate the
T-cell program. Then multiple regulators that are likely contributors to commitment –
GATA-3, Bcl11b, TCF-1, and members of the Runx family – not only are turned on but
remain active in all T-cell subsets at various levels thereafter. The roles of these factors in
commitment may each be more to exclude a particular alternative than to cause “T lineage
commitment” in toto. For example, GATA-3 which helps to block B cell development can
even enhance myeloid development from certain precursors (89). T-cell commitment overall
appears to be a mosaic of separable though interlocking parts.
Much debate has been focused on the right ways to consider hierarchies of relatedness in the
lymphoid lineages based on the order of lineage exclusion. But mechanisms of exclusion
that cause loss of a given developmental potential simply attack the points of vulnerability
of the alternative program. They work based on the minimum number of repression targets
needed to block access to that fate, not on the number of shared regulatory strands that
otherwise make two programs related. Therefore, commitment mechanisms need not operate
in order of a hierarchical “relatedness index” between two fates. The large number of shared
genes between B and T fates leave points of vulnerability in the B-cell specific need for
EBF1 and Pax5, and the T-cell specific need for Notch1, and these genes become foci for
mutual B/T lineage exclusion. Conversely, the persistence of myeloid and dendritic options
in early thymocytes may reflect not a hierchical proximity of these fates to the T-cell
program, but a side effect of the versatility of PU.1. Despite providing a regulatory bridge to
myeloid fates, PU.1-driven Flt3 expression and other growth-promoting effects are crucial
for development of LMPP cells and possibly all prethymic cells. Myeloid potentials, easily
checked by Notch signals in vivo, may simply be a temporary price paid for some other
useful role of PU.1 in the self-renewing “phase 1” regulatory state of the earliest
thymocytes.
If different lineage exclusions are mediated by distinct components of the T-cell program,
each with its own separate regulation, then the idea that different decisions can be made in
nonhierarchical or even variable order, e.g. between fetal and adult precursor cohorts, is not
so problematic. We have much to learn about what controls the activation and coordination
of different parts of the T-cell program, including the mechanisms of action of factors that
play a role in lineage exclusion. However, the identity of T cells emerges not from a simple
command switch but from the network of these factors’ interactions.
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Figure 1. Exclusion of different hematopoietic fate alternatives on the approach to T-cell identity
The figure shows the changes in developmental potential described in the text, in the context
of a likely sequence of hematopoietic precursors from bone marrow to thymic entry (vertical
dashed line) through T-lineage commitment. Graphs below the stages shown represent
levels of potential remaining at each stage for erythroid, myeloid/DC, B, and NK pathway
alternative. In each case, “potential” is defined as an ability of a normal, unmodified cell to
differentiate to a given fate when the cell is simply transferred to a permissive
microenvironment. The uncertainty about different precursor types that may seed the thymus
is shown as dual paths leading to thymic entry. A dip in “T cell potential” below the CLPs
represents a subset of CLPs with reduced but detectable T cell potential. The apparent
conditional decrease in myeloid potential seen for many prethymic precursors when assayed
in vivo is depicted as a partial decrease of myeloid potential before the thymus, followed by
a plateau of continuing potential until this fate is excluded by cell-intrinsic mechanisms at a
later stage within the thymus. Cell types: HSC, hematopoietic stem cell; MPP, multipotent
precursor; LMPP, lymphoid-primed multipotent precursor; ELP, early lymphoid precursor;
CLP, common lymphoid precursor; DN1/ETP, c-Kit++ CD44+ CD25- DN cells (CD4- CD8-
TCR- Lin- early T cells); DN2a, c-Kit++ CD44+ CD25+ DN cells; DN2b, c-Kit+ CD44+
CD25+ DN cells; DN3a, c-Kitlow CD44low CD25+ DN cells; DN3b, c-Kitlow CD44low
CD25+ DN cells undergoing CD27 and CD28 upregulation and size increase triggered by β-
selection. Later stages of αβ T cell development, not shown, include differentiation to CD4+
CD8+ cells after β-selection followed by selection of a few chosen survivors into CD4+ or
CD8+ fates.
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